1. Home
  2. TRML

TRML

Tourmaline Bio Inc.

Logo Tourmaline Bio Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:31pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Founded: 2021 Country:
United States
United States
Employees: 28 City: NEW YORK
Market Cap: 401.6M IPO Year: N/A
Target Price: $61.80 AVG Volume (30 days): 396.3K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.87 EPS Growth: N/A
52 Week Low/High: $9.18 - $48.31 Next Earning Date: 05-15-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: